阿替普酶与尿激酶在急性肺栓塞溶栓治疗中的效果对比分析

Comparative analysis of the effects of Alteplase and urokinase in thrombolytic therapy for acute pulmonary embolism

目的对比分析阿替普酶与尿激酶在急性肺栓塞溶栓治疗中的效果差异。方法 50例急性肺栓塞溶栓患者,按照随机数字表法分为治疗组和对照组,每组25例。治疗组患者给予阿替普酶治疗,对照组患者给予尿激酶治疗。对比两组患者的治疗效果、不良反应发生率、死亡率、动脉收缩压、肺动脉收缩压、动脉血氧分压。结果治疗组治疗总有效率为88.0%(22/25),高于对照组的56.0%(14/25),差异具有统计学意义(χ~2=6.349, P<0.05)。治疗组患者不良反应发生率为8.0%(2/25),低于对照组的32.0%(8/25),差异具有统计学意义(χ~2=4.500, P<0.05)。治疗组患者死亡率为4.0%,低于对照组的24.0%,差异具有统计学意义(χ~2=4.153, P<0.05)。治疗组患者动脉收缩压、动脉血氧分压高于对照组,肺动脉收缩压低于对照组,差异具有统计学意义(P<0.05)。结论阿替普酶与尿激酶在急性肺栓塞溶栓治疗中的效果差异较明显,阿替普酶在治疗中有一定的优越性,不良反应发生率较低,死亡率较低,值得临床推广和应用。

Objective To compare and analyze the difference between the efficacy of Alteplase and urokinase in thrombolytic therapy for acute pulmonary embolism. Methods A total of 50 acute pulmonary embolism patients with thrombolytic therapy were divided into treatment group and control group according to the random number table method, 25 cases in each group. Patients in the treatment group were treated with Alteplase, patients in the control group were treated with urokinase. The treatment effect, incidence of adverse reactions, mortality, arterial systolic blood pressure, pulmonary arterial systolic blood pressure, arterial oxygen partial pressure between the two groups were compared. Results The total effective rate of the treatment group was 88.0%（22/25）, which was significantly higher than 56.0%（14/25） of the control group, the difference was statistically signficant（χ^2=6.349, P〈0.05）. The incidence of adverse reactions in the treatment group was 8.0%（2/25）, which was significantly lower than 32.0%（8/25） in the control group, the difference was statistically significant（χ^2=4.500, P〈0.05）. The mortality of the treatment group was 4.0%, which was significantly lower than 24.0% of the control group, the difference was statistically significant（χ^2=4.153, P〈0.05）. The arterial systolic blood pressure and arterial oxygen partial pressure of the treatment group were significantly higher than those of the control group, and the pulmonary arterial systolic blood pressure of the treatment group was significantly lower than that of the control group, the differences were statistically significant（P〈0.05）. Conclusion The effect difference of Ateplase and urokinase in thrombolytic therapy for acute pulmonary embolism is obvious, Ateplase has certain advantages in treatment, low incidence of adverse reactions and mortality, is worthy of clinical promotion and application.